Results
VTE, venous thromboembolism
There were 1867 out of 1904 patients enrolled in the prospective EPOC study who had complete follow-up data available at 90 days postoperatively (follow-up rate of 97%) and who provided informed consent. There were 40 patients with missing data for ASA (2%), 28 with missing data for whether routine DUS was used (2%), 15 with missing data for day first mobilized (1%), 10 with missing data for smoking status (0.6%), 10 with missing data for prophylaxis duration (0.5%), two with missing data for history of previous of VTE (0.1%) and one patient with missing data for type of anesthesia (0.05%).Baseline demographic data for patients by VTE prophylaxis subgroup is listed in Table In the aspirin group, there were lower proportions of patients with a history of a prior VTE, undergoing TKA, undergoing bilateral arthroplasty, receiving neuraxial anesthesia and having an ASA grade more than 2, and a higher proportion of patients who were mobilized early and receiving greater than or equal to 14 days of VTE prophylaxis. There were no other significant differences in baseline demographic information.The median duration of prophylaxis in the aspirin group was 42 days (interquartile range (IQR) 35 to 42 days), was 15 days (IQR 10 to 25 days) in the LMWH only group, was 23 days (IQR 11 to 42 days)in the LMWH and aspirin group and was 27 days (IQR 17 to 36) in the DOAC group.
Demographic data by subgroup of venous thromboembolism prophylaxis usedAge(yrs, mean, SD)Body-mass index(kg/mCurrent Smoker(n, Bilateral Joint(n, History of previous venous thromboembolism(n, %)Spinal or Epidural Anaesthesia(n, %)Prophylaxis Duration ≥ 14 days(n, %)Prophylaxis Duration(median, IQR)No. Patients Mobilised by end of Day 1(n, %)